Dr Steven Bradshaw is an experienced life sciences consultancy thought leader with expertise gained from a career spanning value strategy consultancy and healthcare roles.
Steve has comprehensive experience and knowledge of market access and pricing dynamics, and of healthcare systems and pharmaceutical policy affairs across Europe, the US and the emerging markets. Qualified as a MD, trained as an Eye Surgeon, elected as a National Guideline Development Group Committee Member, appointed as Editor at Nature and with life science consultancy experience in all key therapy areas, plus experienced in health economics and outcomes research, including real-world evidence and publication strategy. In the consultancy sector Steven worked with United Biosource Corporation (UBC), Evidera, and he built up and led European capabilities for MKTXS until 2016, prior to founding Valid Insight.
Steve has a first-class BSc (Hons.) in Biochemistry, MD from Cambridge, and specialist Diploma from the Royal College of Ophthalmologists. He is an active member of the market access community: he presents widely, is a frequent attender at panel sessions and congresses and has over 30 publications. His research interests focus on policies for innovative medicines, particularly regenerative medicines for rare disease.
Dr Bradshaw is an expert reviewer for clinical and industry journals and ISPOR, an Advisory Board Member at Pharma-IQ, an Advisor to AuthorAID and has been quoted in publications such as BioPharm Insight, Hospital Pharmacy Europe, Pharmiweb and Reuters.
Dr Steven Bradshaw